AbCellera Biologics (ABCL)

The company is best known for its antibody discovery platform, which is designed to search large immune repertoires and identify rare antibodies with desirable binding and functional properties. AbCellera applies this capability across several modalities, including conventional monoclonal antibodies, multispecific antibodies, and antibody-drug conjugates. Its pipeline includes clinical-stage candidates, programs in IND- or CTA-enabling development, and a larger set of active discovery projects across multiple disease areas.

AbCellera has also operated through partnerships with pharmaceutical and biotechnology companies, giving collaborators access to its discovery capabilities while allowing AbCellera to retain varying economic interests in resulting programs. At the same time, it is building more of its own drug development infrastructure, including capabilities that support internal programs and deeper participation in downstream value creation.

For investors, ABCL represents exposure to a platform biotechnology model rather than a single-product company. Its long-term value depends on the quality of its antibody discovery engine, the clinical success of its partnered and internal candidates, and its ability to convert scientific capabilities into approved medicines for diseases with substantial unmet need.